APA aipamena

Mori, M., Kaneko, N., Ueno, Y., Yamada, M., Tanaka, R., Saito, R., . . . Kuromitsu, S. (2017). Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs.

Chicago Style aipamena

Mori, Masamichi, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Rika Saito, Itsuro Shimada, Kenichi Mori, and Sadao Kuromitsu. "Gilteritinib, a FLT3/AXL Inhibitor, Shows Antileukemic Activity in Mouse Models of FLT3 Mutated Acute Myeloid Leukemia." Invest New Drugs 2017.

MLA aipamena

Mori, Masamichi, et al. "Gilteritinib, a FLT3/AXL Inhibitor, Shows Antileukemic Activity in Mouse Models of FLT3 Mutated Acute Myeloid Leukemia." Invest New Drugs 2017.